ZNF385A Knockout cell line (A-375)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZNF385A (zinc finger protein 385A) encodes a zinc finger-containing regulatory protein that may function through interactions with nucleic acids or other proteins. Members of the ZNF385 family have been reported to participate in transcriptional regulation and to bind single- or double-stranded RNA. These properties suggest potential roles in regulation of gene expression and RNA metabolism, although the specific molecular targets and physiological functions of ZNF385A remain incompletely characterized.

The A375 cell line is a highly characterized human malignant melanoma model derived from a 54-year-old female patient. As referenced in image_2f51f1.png, this adherent cell line demonstrates robust translational performance in in vivo xenograft studies, reliably producing rapidly growing amelanotic melanomas when inoculated into anti-thymocyte serum-treated NIH Swiss mice. Serving as a globally recognized preclinical oncology platform, it is extensively utilized for investigating melanoma disease progression, executing high-throughput screening of novel therapeutics, and studying targeted signaling pathways in skin cancers.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.